Sangamo Therapeutics Inc

NASDAQ: SGMO
$0.45
+$0.02 (+3.7%)
Closing Price on July 12, 2024

SGMO Chart and Intraday Price

SGMO Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 501 CANAL BLVD, POINT RICHMOND TECH CNTR., RICHMOND, CA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 196.86M USD
Shares Outstanding 177,347,000
Sangamo Therapeutics Inc is at the forefront of genomic medicine, working to develop transformative treatments for serious diseases. With a focus on gene therapy, cell therapy, and genome editing, the company's pipeline includes potential therapies for Fabry disease, hemophilia A, sickle cell disease, and prevention of kidney transplant rejection. Based in Brisbane, California, Sangamo is collaborating with leading biopharmaceutical companies to advance its clinical trials and preclinical research, aiming to change the lives of patients and families affected by genetic diseases.

SGMO Articles

Tuesday's top analyst upgrades and downgrades included American Tower, Best Buy, Dominion Energy, Intuit, NetEase, Shell, Southwest Airlines, State Street and Union Pacific.
Monday's additional top analyst upgrades and downgrades included BioMarin Pharmaceutical, Micron Technology, Quanta Services, Sangamo Therapeutics, Silvergate Capital, T. Rowe Price and Zendesk.
Tuesday's top analyst upgrades and downgrades included Ambarella, Annaly Capital Management, Cinedigm, Fortinet, Kinder Morgan, 3M, Nikola, Nvidia, Tesla, Uber Technologies and YETI.
Many of the larger biotechnology and pharmaceutical companies have changed strategies from making acquisitions of speculative biotech outfits. In many cases it is far cheaper to just partner up with...
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.
Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer.
Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing certain diseases.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Alphabet, Amarin, Apple, AutoNation, BlackRock, E*Trade, Etsy, Kellogg and PG&E.
The top analyst upgrades, downgrades and initiations seen on Friday included ArcelorMittal, Barclays, Cree, Ctrip.com, Michael Kors, PVH, Skyworks Solutions, TripAdvisor, YRC Worldwide and Yelp.
If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.
Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences.
Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer.
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study be...
While some of the price targets discussed here call for a stock to double, or even to rise exponentially, it is important to understand that there is a much larger risk when an analyst calls for such...
Jefferies has picked out a few companies in the biotech industry that stand to win big over the coming year.